James Rae, PhD
Thomas H Simpson Collegiate Professor of Cancer Research
Associate Professor of Internal Medicine
Associate Professor of Pharmacology
[email protected]

Available to mentor
James Rae, PhD
Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
      Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar H-J, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium . Clin Pharmacol Ther, 2024 Sep; 116 (3): 690 - 702. DOI:10.1002/cpt.3238
      PMID: 38494911
    • Journal Article
      Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances.
      Bryant AK, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles KM, Rae JM, Tate A, Pearson AN, Jiang R, Fritsche L, Lawrence TS, Zou W, Schipper M, Ramnath N, Yoo S, Crivelli S, Green MD. Cancer Med, 2024 Jun; 13 (12): e7253 DOI:10.1002/cam4.7253
      PMID: 38899720
    • Journal Article
      Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
      Liang Y, Gersch CL, Lehman J, Henry NL, Smith KL, Rae JM, Stearns V, Hertz DL. Pharmacogenet Genomics, 2024 Jun 1; 34 (4): 126 - 129. DOI:10.1097/FPC.0000000000000522
      PMID: 38359166
    • Proceeding / Abstract / Poster
      Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
      Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Hayes DF, Rae JM, Baehner F, Sharma P, Kalinsky K. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 508 - 508. DOI:10.1200/jco.2024.42.16_suppl.508
    • Journal Article
      Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.
      Rattsev I, Stearns V, Blackford AL, Hertz DL, Smith KL, Rae JM, Taylor CO. JAMIA Open, 2024 Apr; 7 (1): ooae006 DOI:10.1093/jamiaopen/ooae006
      PMID: 38250582
    • Proceeding / Abstract / Poster
      Abstract 708: Targeting aurora kinase B (AURKB) as a radiosensitizing strategy in syngeneic models of triple negative breast cancer (TNBC)
      Jungles KM, Wang Z, Bishop C, Wilson C, Liu M, James J, Green M, Rae JM, Speers CW, Pierce LJ. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 708 - 708. DOI:10.1158/1538-7445.am2024-708
    • Journal Article
      LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines
      Thompson EW, Waltham M, Ramus SJ, Hitchins AM, Armes JE, Campbell IG, Williams ED, Thompson PR, Rae J, Johnson MD, Clarke R. Clinical and Experimental Metastasis, 2024 Jan; 21 (6): 535 - 541. DOI:10.1007/s10585-004-4117-z
    • Presentation
      Novel Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer
      2024 Jan;